In vivo effects of recombinant interleukin-11 on myelopoiesis in mice

Giao Hangoc, Tinqqui Yin, Scott Cooper, Paul Schendel, Yu Chung Yang, Hal Broxmeyer

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

Original languageEnglish
Pages (from-to)965-972
Number of pages8
JournalBlood
Volume81
Issue number4
StatePublished - Feb 15 1993

Fingerprint

Myelopoiesis
Interleukin-11
Granulocyte-Macrophage Progenitor Cells
Macrophages
Megakaryocyte-Erythroid Progenitor Cells
Neutrophils
Bone Marrow
Hematopoietic System
Erythroid Precursor Cells
Regain
Hematopoiesis
Platelets
Thigh
Platelet Count
Granulocytes
Cyclophosphamide
Bone
Reference Values
Blood
Spleen

ASJC Scopus subject areas

  • Hematology

Cite this

Hangoc, G., Yin, T., Cooper, S., Schendel, P., Yang, Y. C., & Broxmeyer, H. (1993). In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood, 81(4), 965-972.

In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. / Hangoc, Giao; Yin, Tinqqui; Cooper, Scott; Schendel, Paul; Yang, Yu Chung; Broxmeyer, Hal.

In: Blood, Vol. 81, No. 4, 15.02.1993, p. 965-972.

Research output: Contribution to journalArticle

Hangoc, G, Yin, T, Cooper, S, Schendel, P, Yang, YC & Broxmeyer, H 1993, 'In vivo effects of recombinant interleukin-11 on myelopoiesis in mice', Blood, vol. 81, no. 4, pp. 965-972.
Hangoc G, Yin T, Cooper S, Schendel P, Yang YC, Broxmeyer H. In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood. 1993 Feb 15;81(4):965-972.
Hangoc, Giao ; Yin, Tinqqui ; Cooper, Scott ; Schendel, Paul ; Yang, Yu Chung ; Broxmeyer, Hal. / In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. In: Blood. 1993 ; Vol. 81, No. 4. pp. 965-972.
@article{50c9b05d98f04c6db35829ff737d1d42,
title = "In vivo effects of recombinant interleukin-11 on myelopoiesis in mice",
abstract = "Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.",
author = "Giao Hangoc and Tinqqui Yin and Scott Cooper and Paul Schendel and Yang, {Yu Chung} and Hal Broxmeyer",
year = "1993",
month = "2",
day = "15",
language = "English",
volume = "81",
pages = "965--972",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - In vivo effects of recombinant interleukin-11 on myelopoiesis in mice

AU - Hangoc, Giao

AU - Yin, Tinqqui

AU - Cooper, Scott

AU - Schendel, Paul

AU - Yang, Yu Chung

AU - Broxmeyer, Hal

PY - 1993/2/15

Y1 - 1993/2/15

N2 - Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

AB - Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

UR - http://www.scopus.com/inward/record.url?scp=0027459101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027459101&partnerID=8YFLogxK

M3 - Article

C2 - 8428003

AN - SCOPUS:0027459101

VL - 81

SP - 965

EP - 972

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -